These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19769942)

  • 1. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation.
    Sugimoto T; Tomita A; Hiraga J; Shimada K; Kiyoi H; Kinoshita T; Naoe T
    Biochem Biophys Res Commun; 2009 Dec; 390(1):48-53. PubMed ID: 19769942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
    El-Khoury V; Breuzard G; Fourré N; Dufer J
    Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.
    You JS; Kang JK; Lee EK; Lee JC; Lee SH; Jeon YJ; Koh DH; Ahn SH; Seo DW; Lee HY; Cho EJ; Han JW
    Oncogene; 2008 Feb; 27(10):1376-86. PubMed ID: 17828306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
    Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K; Yamazaki T; Sawada U; Ishizuka H; Aizawa S
    Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
    Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy in B-NHL cell line using adenovirus-mediated transfer of secretable trimeric TRAIL gene expression driven by CD20 promoter.
    Yuan XF; Peng HW; Ding YH; Yan CH; Zhang YJ; Yang M; Xiong DS
    Exp Hematol; 2013 Mar; 41(3):221-30. PubMed ID: 23142221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
    Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
    Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
    Kawabata KC; Ehata S; Komuro A; Takeuchi K; Miyazono K
    Oncogene; 2013 Apr; 32(16):2096-106. PubMed ID: 22665052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP; Anderson KC
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation.
    Demers M; Couillard J; Giglia-Mari G; Magnaldo T; St-Pierre Y
    Biochem Biophys Res Commun; 2009 Sep; 387(3):425-9. PubMed ID: 19596268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells.
    Lai JC; Wu JY; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Anticancer Res; 2009 Jul; 29(7):2535-40. PubMed ID: 19596925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
    Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.
    Tomita A; Hiraga J; Kiyoi H; Ninomiya M; Sugimoto T; Ito M; Kinoshita T; Naoe T
    Int J Hematol; 2007 Jul; 86(1):49-57. PubMed ID: 17675267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
    Mattila AM; Meri S
    Scand J Immunol; 2008 Aug; 68(2):159-68. PubMed ID: 18702746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.